临床心身疾病杂志
臨床心身疾病雜誌
림상심신질병잡지
JOURNAL OF CLINICAL PSYCHOSOMATIC DISEASES
2015年
1期
29-31
,共3页
难治性抑郁症%文拉法辛%丁螺环酮%联合治疗%汉密顿抑郁量表
難治性抑鬱癥%文拉法辛%丁螺環酮%聯閤治療%漢密頓抑鬱量錶
난치성억욱증%문랍법신%정라배동%연합치료%한밀돈억욱량표
TRD%vanlanfaxine%buspirone%therapeutic alliance%HAMD
目的:探讨文拉法辛联合丁螺环酮治疗难治性抑郁症的临床疗效和安全性。方法将60例难治性抑郁症患者随机分为两组,均口服文拉法辛治疗,联合组联合丁螺环酮治疗,观察4周。于治疗前后采用汉密顿抑郁量表评定临床疗效,副反应量表评定不良反应。结果治疗4周末联合组显效率为77.4%、有效率为87.1%,对照组分别为42.5%、85.0%,联合组显效率、有效率显著高于对照组(χ2=13.02、5.01,P<0.05或0.01)。两组不良反应较轻微,主要表现为恶心、出汗、头疼等。结论文拉法辛联合丁螺环酮治疗难治性抑郁症具有增效作用,疗效显著,起效快,不增加不良反应,显著优于单用文拉法辛治疗。
目的:探討文拉法辛聯閤丁螺環酮治療難治性抑鬱癥的臨床療效和安全性。方法將60例難治性抑鬱癥患者隨機分為兩組,均口服文拉法辛治療,聯閤組聯閤丁螺環酮治療,觀察4週。于治療前後採用漢密頓抑鬱量錶評定臨床療效,副反應量錶評定不良反應。結果治療4週末聯閤組顯效率為77.4%、有效率為87.1%,對照組分彆為42.5%、85.0%,聯閤組顯效率、有效率顯著高于對照組(χ2=13.02、5.01,P<0.05或0.01)。兩組不良反應較輕微,主要錶現為噁心、齣汗、頭疼等。結論文拉法辛聯閤丁螺環酮治療難治性抑鬱癥具有增效作用,療效顯著,起效快,不增加不良反應,顯著優于單用文拉法辛治療。
목적:탐토문랍법신연합정라배동치료난치성억욱증적림상료효화안전성。방법장60례난치성억욱증환자수궤분위량조,균구복문랍법신치료,연합조연합정라배동치료,관찰4주。우치료전후채용한밀돈억욱량표평정림상료효,부반응량표평정불량반응。결과치료4주말연합조현효솔위77.4%、유효솔위87.1%,대조조분별위42.5%、85.0%,연합조현효솔、유효솔현저고우대조조(χ2=13.02、5.01,P<0.05혹0.01)。량조불량반응교경미,주요표현위악심、출한、두동등。결논문랍법신연합정라배동치료난치성억욱증구유증효작용,료효현저,기효쾌,불증가불량반응,현저우우단용문랍법신치료。
Objective To explore the efficacy and safety of venlafaxine combined with buspirone in the treatment of treatment‐resistant depression (TRD) .Methods Sixty TRD patients were randomly divided into two groups both taking orally venlafaxine ,combination group was plus buspi‐rone for 4 weeks .Efficacies were assessed with the Hamilton Depression Scale (HAMD) before and after treatment and adverse reactions with the Treatment Emergent Symptom Scale (TESS) .Results At the end of the 4th week obvious effective and effective rate were respectively 77 .4% and 87 .1% in combination group and 42 .5% and 85 .0% in control group ,the former was significantly higher than the latter (χ2 =13 .02 ,5 .01 ;P<0 .05 or 0 .01) .Adverse reactions of both groups were mild and mainly nausea ,diaphore‐sis ,headache and so on .Conclusion Venlafaxine combined with buspirone has a synergism and an evident effect ,takes effect more rapidly ,and doesn’t increase adverse reactions compared with single venlafaxine in the treatment of treatment‐resistant depression .